Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$278.09
$300.18
$273.11
$495.55
$37.13B0.291.14 million shs2.20 million shs
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$8.00
$8.11
$5.39
$12.23
$1.23B1.786.15 million shs8.65 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.21
0.0%
$23.00
$13.15
$27.72
$12.10B1.695.99 million shs10.24 million shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.55
$14.55
$9.20
$18.67
$6.84B0.32121 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%-1.68%-7.46%-10.92%-10.96%
Array Technologies, Inc. stock logo
ARRY
Array Technologies
0.00%+2.96%-2.44%+19.40%+6.10%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+0.07%+13.64%+0.97%+81.27%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%0.00%+3.93%+35.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$278.09
$300.18
$273.11
$495.55
$37.13B0.291.14 million shs2.20 million shs
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$8.00
$8.11
$5.39
$12.23
$1.23B1.786.15 million shs8.65 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.21
0.0%
$23.00
$13.15
$27.72
$12.10B1.695.99 million shs10.24 million shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.55
$14.55
$9.20
$18.67
$6.84B0.32121 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%-1.68%-7.46%-10.92%-10.96%
Array Technologies, Inc. stock logo
ARRY
Array Technologies
0.00%+2.96%-2.44%+19.40%+6.10%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+0.07%+13.64%+0.97%+81.27%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%0.00%+3.93%+35.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.85
Moderate Buy$463.1366.54% Upside
Array Technologies, Inc. stock logo
ARRY
Array Technologies
2.33
Hold$10.4230.26% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.79
Moderate Buy$28.5517.91% Upside
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ARRY, ALNY, OPHLF, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/4/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Reiterated RatingBuy$510.00
5/27/2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
UpgradeSell (E+)Sell (D-)
5/19/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Initiated CoverageBuy$380.00
5/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
UpgradeStrong-Buy
5/12/2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
DowngradeSell (D-)Sell (E+)
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/7/2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Reiterated RatingBuy$12.00
5/7/2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Boost Price TargetBuy$10.00 ➝ $11.00
5/7/2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Boost Price TargetOverweight$9.00 ➝ $10.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B10.00$2.80 per share99.46$5.97 per share46.58
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$1.21B1.02$2.00 per share4.00($1.35) per share-5.93
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.56$2.32 per share10.44$13.18 per share1.84
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.43B2.00$1.08 per share13.50$11.07 per share1.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$3.6675.9826.43N/A11.72%85.76%10.32%7/30/2026 (Estimated)
Array Technologies, Inc. stock logo
ARRY
Array Technologies
-$52.24M-$0.84N/A9.881.13-5.56%-103.11%9.13%8/6/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.841.59-4.95%7.42%3.66%8/6/2026 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$463.46M$0.9914.7017.74N/A13.51%8.55%6.58%8/3/2026 (Estimated)

Latest ARRY, ALNY, OPHLF, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Array Technologies, Inc. stock logo
ARRY
Array Technologies
-$0.06$0.06+$0.12-$0.09$201.66 million$223.41 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
4/30/2026Q1 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Array Technologies, Inc. stock logo
ARRY
Array Technologies
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.94
3.13
3.06
Array Technologies, Inc. stock logo
ARRY
Array Technologies
N/A
2.25
1.82
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.10
3.02
2.56

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Array Technologies, Inc. stock logo
ARRY
Array Technologies
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.51 million132.37 millionOptionable
Array Technologies, Inc. stock logo
ARRY
Array Technologies
1,200153.83 million152.84 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
4,287469.91 millionN/ANot Optionable

Recent News About These Companies

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$278.09 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$276.38 -1.71 (-0.62%)
As of 06/18/2026 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Array Technologies stock logo

Array Technologies NASDAQ:ARRY

$8.00 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$7.91 -0.09 (-1.18%)
As of 06/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products portfolio includes DuraTrack HZ v3, a single axis tracker; Array STI H250 that delivers a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance energy production. Array Technologies, Inc. was incorporated in 1987 and is headquartered in Albuquerque, New Mexico.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.21 -0.01 (-0.04%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$23.63 -0.58 (-2.40%)
As of 06/18/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$14.55 0.00 (0.00%)
As of 06/18/2026

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.